Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others), By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others), By Region, and By Competition

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4900

Multi-User Licence

$5900

Custom Research Licence

$8900

Summary

Request Sample

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 4.66 billion
CAGR (2023-2028)	7.02%
Fastest Growing Segment	Hyaluronic Acid Injections
Largest Market	North America

Market Overview

Global Joint Pain Injections Market has valued at USD 4.66 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.02% through 2028. The global joint pain injections market is a dynamic segment of the healthcare industry that addresses the growing prevalence of joint-related conditions, particularly osteoarthritis and rheumatoid arthritis. Joint pain injections offer a non-surgical and minimally invasive treatment option for individuals suffering from chronic joint pain and inflammation. These injections typically consist of corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), or other medications designed to alleviate pain, reduce inflammation, and improve joint function.

Key Market Drivers

Rising Obesity Rates

Obesity, a worldwide health concern, has become an epidemic that extends beyond the issue of body image to one of profound health implications. It's not just about fitting into smaller clothes but also about managing the serious health problems that often accompany obesity. Among these issues, joint pain is a prominent concern, and it's a primary driver of the growing global market for joint pain injections.

Obesity is a complex and multifaceted health issue. It's characterized by an excessive accumulation of body fat and is commonly measured using the body mass index (BMI). A BMI of 30 or higher is considered obese, and the condition affects people of all ages, races, and socioeconomic backgrounds.

The global prevalence of obesity has surged over the past few decades, making it a pressing public health issue. The World Health Organization (WHO) reports that worldwide obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults were overweight, and over 650 million were obese. This trend is alarming not only because of its implications for conditions like heart disease and diabetes but also because of its significant impact on musculoskeletal health, leading to joint pain and mobility issues.

The additional weight places increased pressure on the joints, particularly the knees, hips, and lower back. This added load can accelerate the degeneration of joint tissues. Fat tissue, especially visceral fat, produces inflammatory substances that can contribute to joint inflammation. Inflammation is a key driver of joint pain. Obesity is a significant risk factor for osteoarthritis, a common joint condition. In this disease, the protective cartilage covering the ends of bones breaks down, leading to pain, swelling, and reduced mobility. Obesity often leads to reduced physical activity, which can weaken the muscles supporting the joints. This further compounds joint pain and increases the risk of injury.

With more individuals suffering from obesity-related joint pain, there is a larger patient pool seeking effective solutions. Joint pain injections offer a minimally invasive and efficient way to manage pain and improve mobility, making them an appealing choice for patients. Obesity can complicate surgical procedures, and patients with obesity may face a higher risk of complications during joint replacement surgeries. Joint pain injections provide an alternative to invasive surgical interventions, reducing both risks and costs. Obesity-related joint pain is often chronic, requiring long-term management. Joint pain injections can provide long-lasting relief, allowing patients to maintain a more active lifestyle, despite their weight, and thus fostering patient loyalty to the treatment. As the obesity epidemic garners more attention in the public health sphere, individuals are becoming increasingly aware of the link between obesity and joint pain. This heightened awareness can drive patients to explore joint pain injection options.

Minimally Invasive Approach

Joint pain is a pervasive issue, affecting millions of people around the world and impeding their quality of life. Conditions like osteoarthritis and rheumatoid arthritis can cause chronic discomfort and reduced mobility. In response to this, the global joint pain injections market has emerged as a promising solution, and one of its key drivers of growth is the minimally invasive approach it offers.

A minimally invasive approach in medical procedures involves using techniques that require smaller incisions or no incisions at all, as opposed to traditional open surgeries. These methods aim to minimize trauma to the body, reduce pain, lower the risk of complications, and expedite recovery. When it comes to addressing joint pain, this approach has revolutionized the way patients manage their pain and has greatly contributed to the growth of the joint pain injections market.

Minimally invasive joint pain injections, compared to open surgical procedures, offer a significantly lower risk of complications such as infection, excessive bleeding, or adverse reactions to anesthesia. Patients and healthcare providers both appreciate the decreased likelihood of complications, making injections a safer and more appealing option. Recovery times for minimally invasive procedures are generally shorter. Patients can often return to their normal activities more rapidly than after open surgeries. This shorter recovery period is particularly beneficial for individuals with busy lives or those who want to regain their mobility quickly. Many joint pain injections are performed in outpatient settings, allowing patients to receive treatment without the need for hospitalization. This convenience is a strong driver of patient preference, as it reduces the time and cost associated with inpatient care. Minimally invasive injections typically involve smaller incisions or needle insertions, leading to less tissue damage and, consequently, less pain and discomfort post-procedure. This is a significant selling point for patients seeking relief from joint pain. Since minimally invasive procedures often require less time in the operating room and a shorter hospital stay (or none at all), they are usually more cost-effective than traditional surgeries. This cost-efficiency benefits both patients and healthcare systems. Minimally invasive joint pain injections allow for precise targeting of the affected area. Whether it's a corticosteroid injection, hyaluronic acid injection, or platelet-rich plasma (PRP) injection, these treatments can be precisely administered, increasing their effectiveness. Patients increasingly prefer to have a say in their healthcare decisions. Minimally invasive approaches, including joint pain injections, align with this patient-centric trend. Patients appreciate having choices and being involved in deciding their treatment course. The appeal of minimally invasive treatments extends to a broad demographic, including both the elderly and younger, more active individuals. Younger patients, in particular, appreciate the convenience and quick recovery associated with minimally invasive joint pain injections.

Increased Awareness and Education

Joint pain is a common ailment that affects millions of people worldwide, often due to conditions like osteoarthritis and rheumatoid arthritis. The impact of joint pain on individuals' quality of life can be significant, making effective treatment options a vital necessity. One key driver of the growing global joint pain injections market is increased awareness and education.

In recent years, there has been a notable surge in health awareness campaigns and educational initiatives. These programs are aimed at informing the public about various health conditions, their symptoms, and available treatment options. Joint pain is no exception to this trend, and patients now have access to a wealth of information about the causes, consequences, and treatment choices for their discomfort.

The availability of information empowers patients to take an active role in their healthcare. Informed patients are more likely to discuss their symptoms and potential treatment options with healthcare providers, leading to a more collaborative approach to care. This collaborative model can result in a higher likelihood of joint pain injections being considered and chosen as a treatment method. In the past, there has been a stigma surrounding joint pain conditions, with sufferers often reluctant to seek treatment or share their experiences. Increased awareness campaigns have helped to destigmatize these conditions, making it more socially acceptable to seek treatment. Consequently, patients are more likely to explore and accept joint pain injections as a viable solution. Many awareness initiatives stress the importance of early intervention and preventative care. This focus on prevention and early management has led to the recognition of joint pain injections as a proactive approach to preserving joint health. As a result, more individuals are considering these injections as a means of avoiding chronic pain. Comprehensive health education often emphasizes the importance of a holistic approach to well-being. This means addressing not just the symptoms but also the underlying causes of health conditions. Joint pain injections, which can target both symptoms and causes, align with this holistic approach, making them a valuable component of comprehensive care. In addition to formal education campaigns, online forums, social media communities, and patient support groups have played a significant role in disseminating information about joint pain and its treatments. These platforms facilitate shared experiences, advice, and information exchange, further promoting the use of joint pain injections. Better education about joint pain symptoms has led to early diagnosis and intervention. Patients are now more likely to recognize joint pain conditions before they progress to advanced stages, making joint pain injections a viable early treatment option.

Patient-Centric Care

The landscape of healthcare is evolving, and the concept of patient-centric care is at the forefront of this transformation. As patients become more actively involved in their healthcare decisions, this approach has given rise to new trends and treatments. In the world of pain management, joint pain injections have gained significant traction, thanks in part to the principles of patient-centric care.

Patient-centric care is a healthcare model that prioritizes the individual patient's needs, preferences, and values. It involves actively involving the patient in medical decision-making and tailoring care to their unique circumstances. This approach has profound implications for the management of chronic conditions like joint pain.

In the patient-centric care model, patients play an active role in their healthcare decisions. When it comes to managing joint pain, this means patients have a say in the choice of treatment, including the decision to explore joint pain injections. Healthcare providers work collaboratively with patients to discuss the various options and select the one that best aligns with the patient's goals and preferences. Patients have diverse experiences with joint pain, and what works for one person may not work for another. Patient-centric care recognizes this individuality and tailors treatment plans to the patient's specific needs. Joint pain injections, with their various options, offer a versatile choice that can be customized to each patient's condition. When patients feel heard and respected in their care, their satisfaction with the healthcare experience increases. Joint pain injections are known for their effectiveness and minimally invasive nature, making them an appealing option for patients who desire efficient and patient-centric pain management. Patients who actively participate in their care decisions and understand their treatment options are more likely to adhere to their treatment plans. This can lead to better outcomes for conditions like joint pain. Joint pain injections, which are relatively straightforward and low-risk, are often more attractive to patients, increasing the likelihood of treatment adherence. The patient-centric care model aims to reduce the physical and emotional burden on patients. Joint pain injections, as minimally invasive procedures, are often less disruptive to daily life compared to surgical interventions, aligning well with the model's goal of minimizing patient inconvenience. Patient-centric care places a strong emphasis on improving the patient's quality of life. Joint pain injections, by reducing pain, increasing mobility, and enhancing overall well-being, are aligned with this central goal.

Download Free Sample Report

Key Market Challenges

Reimbursement Issues

Reimbursement policies and insurance coverage can significantly affect the adoption of joint pain injections. Patients may be less inclined to choose these treatments if they are not adequately covered by their insurance, as the out-of-pocket costs can be substantial. Ensuring broader insurance coverage and reimbursement support is crucial for the market's expansion.

Competition and Pricing Pressures

The global joint pain injections market is competitive, with numerous pharmaceutical and medical device companies offering their products. This competition can lead to pricing pressures, potentially resulting in reduced profit margins and the need for cost-effective production and marketing strategies to maintain profitability.

Variability in Patient Response

Not all patients respond to joint pain injections in the same way. Some may experience significant pain relief and improved mobility, while others may not derive the same benefits. This variability in patient response can be a challenge, as it underscores the need for personalized treatment plans and a better understanding of which patients are most likely to benefit from these injections.

Key Market Trends

Advancements in Biologics and Regenerative Therapies

Biologics, such as platelet-rich plasma (PRP) injections, are gaining prominence in the treatment of joint pain. These therapies use a patient's own cells and growth factors to stimulate tissue repair and regeneration. The development of more sophisticated biologics and regenerative therapies is expected to provide longer lasting and more significant pain relief for joint pain sufferers.

AI and Data Analytics for Treatment Optimization

Artificial intelligence (AI) and data analytics are increasingly being used to optimize joint pain injection treatments. These technologies can assist healthcare providers in identifying the most suitable treatment for a patient based on their medical history, lifestyle, and the latest research. AI-driven treatment recommendations may improve the precision and effectiveness of joint pain injections.

Expanding Geographical Reach

While North America and Europe have traditionally dominated the joint pain injections market, there is a growing interest and investment in emerging markets, particularly in the Asia-Pacific region. As healthcare infrastructure and patient awareness improve, the market's geographical reach is set to expand, creating new growth opportunities.

Segmental Insights

Type of Injection Insights

Based on the category of Type of Injection, the Hyaluronic Acid Injections sector is poised for growth in the foreseeable future. These injections are employed to alleviate knee pain associated with osteoarthritis (OA) in patients who have already attempted ineffective treatments like acetaminophen and other pain relievers. Hyaluronic acid injections have gained popularity as a non-surgical therapeutic option, particularly due to clinicians' hesitancy to administer repeated corticosteroid injections into the joints.

Market participants are actively engaged in the development of innovative products with numerous advantages, frequently introducing new offerings. For example, in August 2021, Seikagaku Corporation introduced HyLink, a single-injection Visco supplement for intra-articular use in treating knee osteoarthritis in Taiwan through TCM Biotech International Corp. The primary ingredient is a cross-linked hyaluronate hydrogel created using cross-linking technology. These product launches are expected to drive growth in this segment during the forecast period.

Application Insights

Based on Application, the Knee & Ankle segment is poised to capture a significant market share in the Global Joint Pain Injections Market during the forecast period for several compelling reasons. Firstly, knee and ankle joints are particularly susceptible to wear and tear, making them more prone to conditions like osteoarthritis and sports-related injuries, driving the demand for pain-relieving injections. Secondly, the rise in the aging population, combined with the growing prevalence of joint-related issues, has increased the patient pool seeking effective non-surgical solutions. Additionally, advancements in injection technologies and the development of specialized products tailored to the specific needs of the knee and ankle joints have made these injections more efficient and accessible. Furthermore, patients and healthcare providers increasingly prefer these injections over surgical interventions, making the Knee & Ankle segment a promising growth area within the Joint Pain Injections Market.

Download Free Sample Report

Regional Insights

In the forthcoming period, North America is poised to maintain its dominant position in the Joint Pain Injections Market. This can be attributed to several key factors. Firstly, the region faces a high prevalence of musculoskeletal disorders, driven in part by a growing aging population. Secondly, the strong presence of industry leaders in North America, coupled with superior healthcare infrastructure, has facilitated the growth of this market. Furthermore, there is a heightened level of awareness among both the public and healthcare professionals regarding available technologies. Additionally, North America boasts a concentration of major market players who are actively investing in research activities, further bolstering market growth.

According to the Centers for Disease Control and Prevention (CDC), millions of individuals in the United States grapple with chronic pain stemming from arthritis annually. The adoption of advanced technologies is a noteworthy catalyst for market expansion in this region. Moreover, demographic trends support this trend, as the Population Reference Bureau estimates that by 2060, there will be approximately 95 million Americans aged 65 and older, constituting 23% of the total population. In Canada, the 2021 census conducted by Statistics Canada revealed an estimated 7,021,430 individuals aged 65 and above, of which 3,224,680 were male and 3,796,750 were female. This surge in the geriatric population is anticipated to drive demand for joint pain injections and, consequently, foster market growth in the region.

Recent Developments

In March 2022, Green Roads, a subsidiary of the Valens Company, contributed a substantial sum of USD 120,000 to the Arthritis Foundation in a show of support for the organization's pain management initiative aimed at enhancing the quality of life for individuals enduring chronic pain. This generous contribution resulted in Green Roads being officially recognized as a supporting sponsor of the Arthritis Foundation.
In January 2022, AbbVie secured approval from the United States Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa) for the treatment of adults dealing with active psoriatic arthritis (PsA). SKYRIZI offers the convenience of a once-quarterly single injection, marking a significant advancement in PsA treatment.

Key Market Players

Anika Therapeutics Inc
Bioventus LLC
Ferring Pharmaceuticals Inc
Sanofi SA
Pfizer Inc
Eli Lilly & Co
Flexion Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Zimmer Biomet Holdings, Inc.

By Type of Injection	By Application	By Region
Steroid Joint Injections Hyaluronic Acid Injections Platelet-rich Plasma (PRP) Injections Placental Tissue Matrix (PTM) Injections Others	Shoulder & Elbow Knee & Ankle Spinal Joints Hip Joint Others	North America Europe Asia-Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Joint Pain Injections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Joint Pain Injections Market, By Type of Injection:

o Steroid Joint Injections

o Hyaluronic Acid Injections

o Platelet-rich Plasma (PRP) Injections

o Placental Tissue Matrix (PTM) Injections

o Others

Joint Pain Injections Market, By Application:

o Shoulder & Elbow

o Knee & Ankle

o Spinal Joints

o Hip Joint

o Others

Joint Pain Injections Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ Germany

§ United Kingdom

§ France

§ Italy

§ Spain

o Asia-Pacific

§ China

§ Japan

§ India

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

§ Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Joint Pain Injections Market.

Available Customizations:

Global Joint Pain Injections market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Joint Pain Injections Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Joint Pain Injections Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

5.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

5.2.3. By Region

5.2.4. By Company (2022)

5.3. Product Market Map

5.3.1. By Type of Injection

5.3.2. By Application

5.3.3. By Region

6. North America Joint Pain Injections Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

6.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

6.2.3. By Country

6.3. North America: Country Analysis

6.3.1. United States Joint Pain Injections Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type of Injection

6.3.1.2.2. By Application

6.3.2. Canada Joint Pain Injections Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type of Injection

6.3.2.2.2. By Application

6.3.3. Mexico Joint Pain Injections Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type of Injection

6.3.3.2.2. By Application

7. Europe Joint Pain Injections Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

7.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Joint Pain Injections Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type of Injection

7.3.1.2.2. By Application

7.3.2. United Kingdom Joint Pain Injections Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type of Injection

7.3.2.2.2. By Application

7.3.3. France Joint Pain Injections Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type of Injection

7.3.3.2.2. By Application

7.3.4. Italy Joint Pain Injections Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type of Injection

7.3.4.2.2. By Application

7.3.5. Spain Joint Pain Injections Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type of Injection

7.3.5.2.2. By Application

8. Asia-Pacific Joint Pain Injections Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

8.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

8.2.3. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Joint Pain Injections Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type of Injection

8.3.1.2.2. By Application

8.3.2. Japan Joint Pain Injections Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type of Injection

8.3.2.2.2. By Application

8.3.3. India Joint Pain Injections Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type of Injection

8.3.3.2.2. By Application

8.3.4. Australia Joint Pain Injections Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type of Injection

8.3.4.2.2. By Application

8.3.5. South Korea Joint Pain Injections Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type of Injection

8.3.5.2.2. By Application

9. South America Joint Pain Injections Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

9.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

9.2.3. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Joint Pain Injections Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type of Injection

9.3.1.2.2. By Application

9.3.2. Argentina Joint Pain Injections Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type of Injection

9.3.2.2.2. By Application

9.3.3. Colombia Joint Pain Injections Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type of Injection

9.3.3.2.2. By Application

10. Middle East and Africa Joint Pain Injections Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)

10.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)

10.2.3. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Joint Pain Injections Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type of Injection

10.3.1.2.2. By Application

10.3.2. Saudi Arabia Joint Pain Injections Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type of Injection

10.3.2.2.2. By Application

10.3.3. UAE Joint Pain Injections Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type of Injection

10.3.3.2.2. By Application

10.3.4. Kuwait Joint Pain Injections Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Type of Injection

10.3.4.2.2. By Application

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development

12.2. Mergers & Acquisitions

12.3. Product Launches

13. Porter’s Five Forces Analysis

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Business Overview

14.2. Product Offerings

14.3. Recent Developments

14.4. Financials (As Reported)

14.5. Key Personnel

14.6. SWOT Analysis

14.6.1. Anika Therapeutics Inc

14.6.2. Bioventus LLC

14.6.3. Ferring Pharmaceuticals Inc

14.6.4. Sanofi SA

14.6.5. Pfizer Inc

14.6.6. Eli Lilly & Co

14.6.7. Flexion Therapeutics Inc

14.6.8. Teva Pharmaceutical Industries Ltd

14.6.9. Zimmer Biomet Holdings, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Joint Pain Injections Market in 2022?

The market size of the Global Joint Pain Injections Market was estimated to be USD 4.66 billion in 2022.

Who are the top players operating in the Global Joint Pain Injections Market in 2022?

Anika Therapeutics Inc, Bioventus LLC, Ferring Pharmaceuticals Inc, Sanofi SA, Pfizer Inc, Eli Lilly & Co, Flexion Therapeutics Inc, Teva Pharmaceutical Industries Ltd, Zimmer Biomet Holdings, Inc. are some of the key players operating in the Global Joint Pain Injections Market.

What are the challenges faced by the Global Joint Pain Injections Market in the upcoming years?

Reimbursement issues, competition and pricing pressures, alternative treatment options, are some of the major challenges faced by the Global Joint Pain Injections Market in the upcoming years.

What are the major drivers for the Global Joint Pain Injections Market?

Rising obesity rates and increased awareness and education are the major drivers for the Global Joint Pain Injections Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Joint Pain Injections Market to Grow with a CAGR of 7.02% through 2028

Nov, 2023

Changing patient preferences, technological advancements, and increasing awareness are expected to drive the Global Joint Pain Injections Market growth in the forecast period, 2024-2028.